.jpg "Strata Skin Sciences Inc (NASDAQ: SSKN)")
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Strata Skin Sciences Inc (NASDAQ: SSKN) and Eyegate (NASDAQ: EYEG) with bullish sentiments.
Strata Skin Sciences Inc (NASDAQ: SSKN)
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Strata Skin Sciences Inc (NASDAQ: SSKN), with a price target of $3. The company’s shares closed yesterday at $1.62.
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -11.2% and a 36.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Strata Skin Sciences Inc has an analyst consensus of Moderate Buy, with a price target consensus of $3.
See today’s analyst top recommended stocks >>
Eyegate (NASDAQ: EYEG)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Eyegate (NASDAQ: EYEG), with a price target of $3. The company’s shares closed yesterday at $0.57.
Selvaraju observed:
“We note that PE is typically characterized by damage to he epithelium of the cornea in a pinpoint pattern. Potential causes of PE may include dry eye disease, blepharitis and bacterial conjunctivitis. The number of patients with corneal epitheliopathies in the U.S. could be over 76M, and current therapies have limited efficacy. Investors may recall that OBG is being developed for the acceleration of re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy (PRK). EyeGate expects to address the outstanding item cited by the FDA in the IDE for PRK in the current quarter. If so, a clinical trial in PE may start in 2H 2018, according to the management. In our view, the addition of PE could significantly expand the addressable market of OBG. In the wake of this update, we reiterate our Buy rating and $3 price target.”
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -1.5% and a 41.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Eyegate has an analyst consensus of Moderate Buy, with a price target consensus of $3.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EYEG:
